Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Angelo TotaroFrancesco PintoDario PuglieseMatteo VittoriMarco RacioppiNazario FoschiPier Francesco BassiEmilio SaccoPublished in: Neurourology and urodynamics (2017)
These results indicated that intraprostatic BTA is safe and can improve LUTS and QoL in patients with BPH and unsatisfactory response to CMT.